Skip to main content

Advertisement

SpringerLink
Log in

Do nothing but observe microprolactinomas: when and how to replace sex hormones?

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Hyperprolactinemia is associated with suppression of the hypothalamic- pituitary–gonadal axis and consequent hypogonadism, manifesting loss of libido, infertility and osteoporosis long-term in both male and female patients, with associated menstrual irregularities, amenorrhea and galactorrhea in women and erectile dysfunction in men. The primary goals of therapy in patients harboring prolactinoma are control of tumor size and normalization of serum PRL, with restoration of gonadal and sexual function and fertility. Clinical manifestations of hypogonadism have variable consequences depending on the age and sex of the patient and desire for fertility. Careful consideration of clinical consequences of hyperprolactinemia in relation to age and sex should help guide therapeutic decision making. Another important consideration in attaining our treatment goals in patients harboring microprolactinomas, is the observation that greater than 90% of microprolactinomas do not enlarge, when followed for 10 years. Treatment options for the management of microprolactinomas include observation alone, with monitoring of serum prolactin levels every 6–12 months, vs initiation of dopamine agonist therapy vs gonadal steroid hormone replacement (using the oral contraceptive or other combination estrogen and progesterone replacement regimens in females or testosterone replacement therapy in males). In the present review, current data related to clinical consequences of microprolactinomas and treatment outcomes at different stages in the lifespan are reviewed, with a suggested algorithm as to whether to treat or not, and an appropriate therapeutic regimen to institute.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

(Adapted from Refs. [40, 41])

Similar content being viewed by others

References

  1. Gillam MP, Molitch ME, Lombardi G, Coloa A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485

    CAS  PubMed  Google Scholar 

  2. Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–1631

    CAS  PubMed  Google Scholar 

  3. Schlechte J, Dolan K, Sherman B, Chap-ler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418

    CAS  PubMed  Google Scholar 

  4. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J (1996) Long-term follow-up of patients with hyperprolactinaemia. Clin Endo 45:299–303

    CAS  Google Scholar 

  5. Rigg LA, Lein A, Yen SS (1977) Patterns of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 129:454–456

    CAS  PubMed  Google Scholar 

  6. Dinč H, Esen F, Demirci A, Sari A, Resit GH (1998) Pituitary dimensions and volume measurements during pregnancy and postpartum. MRI Assess Acta Radiol 39:64–69

    Google Scholar 

  7. Elster AD, Sanders TG, Vines FS, Chen MY (1991) Size and shape of the pituitary gland during pregnancy and post partum Measurement with MR imaging. Radiology 181:531

    CAS  PubMed  Google Scholar 

  8. Gonzales JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy. An in vivo study using magnetic resonance imaging. Am J Med 85:217–220

    Google Scholar 

  9. Huang W, Molitch ME (2019) Pituitary tumors in pregnancy. Endocrinol Metab Clin North Am 48:569–581

    PubMed  Google Scholar 

  10. Molitch ME (2015) Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol 172:R205–R213

    CAS  PubMed  Google Scholar 

  11. Balint-Perić LA, Prelević GM (1997) Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. Gynecol Endocrinol 11:275–280

    PubMed  Google Scholar 

  12. Reyes FI, Winter JS, Faiman CI (1977) Pituitary-ovarian relationships preceding the menopause. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am J Obstet Gynecol 129:557–564

    CAS  PubMed  Google Scholar 

  13. Karunakaran S, Page RC, Wass JA (2001) The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol 54:295–300

    CAS  Google Scholar 

  14. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta- analysis. J Clin Endocrinol Metab 95:43–51

    CAS  PubMed  Google Scholar 

  15. Hu J, Zheng X, Zhang W, Yang H (2015) Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta- analysis. Pituitary 18:745–751

    CAS  PubMed  Google Scholar 

  16. Mallea-Gil MS, Manavela M, Alfieri A, Ballarino MC, Chervin A, Danilowicz K, Diez S et al (2016) Prolactinomas: evolution after menopause. Arch Endocrinol Metab 60:42–46

    PubMed  Google Scholar 

  17. Santharam S, Athanasios F, Arlt MW, Ayuk J, Gittoes N, Toogood A, Karavitaki N (2018) Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol 89:346–353

    CAS  Google Scholar 

  18. Indirli R, Ferrante E, Sala E, Giavoli C, Mantovani G, Arosio M (2019) Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm Cancer 10:120–127

    CAS  PubMed  Google Scholar 

  19. Devi Y, Halperin J (2014) Reproductive actions of prolactin mediated through short and long receptor isoforms. Mol Cell Endocrinol 382:400–410

    Google Scholar 

  20. Mcneilly AS, Robinson JC, Houston MJ et al (1983) Release of oxytocin and prolactin in response to suckling. Br Med J 286:257–259

    CAS  Google Scholar 

  21. Brown RS, Herbison AE, Grattan DR (2014) Prolactin regulation of kisspeptin neurons in the mouse brain and its role in the lactation-induced suppression of kisspeptin expression. J Neuroendocrinol 26:898–908

    CAS  PubMed  Google Scholar 

  22. Demura R, Ono M, Demura H, Shizume K, Oouchi H (1982) Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17b-estradiol in the human ovary. J Clin Endocrinol Metab 54:1246–1250

    CAS  PubMed  Google Scholar 

  23. Krasnow JS, Hickey GJ, Richard JS (1990) Regulation of aromatase mRNA and estradiol biosynthesis in rat ovarian granulosa and luteal cells by prolactin. Mol Endocrinol 4:13–22

    CAS  PubMed  Google Scholar 

  24. Dorrington JH, Gore-Langton RE (1982) Antigonadal action of prolactin: further studies on the mechanism of inhibition of follicle-stimulating hormone-induced aromatase activity in rat granulosa cell cultures. Endocrinology 110:1701–1707

    CAS  PubMed  Google Scholar 

  25. Bouilly J, Sonigo C, Auffret J et al (2012) Prolactin signaling mechanisms in ovary. Mol Cell Endocrinol 356:80–87

    CAS  PubMed  Google Scholar 

  26. Seppala M, Ranta T, Hirvonen E (1976) Hyperprolactinaemia and luteal insufficiency. Lancet 31:229–230

    Google Scholar 

  27. Mazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, Porcelli T, Vescovi PP, De Marinis L, Giustina A (2011) High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14:299–306

    CAS  PubMed  Google Scholar 

  28. Schlechte J, el-Khoury G, Kathol M et al (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021–1026

    CAS  PubMed  Google Scholar 

  29. Klibanski A, Biller BMK, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Eects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67:124–130

    CAS  PubMed  Google Scholar 

  30. Seriwatanachai D, Krishnamra N, van Leeuwen JPTM (2009) Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 107:677–685

    CAS  PubMed  Google Scholar 

  31. Tomlinson JW, Holden N, Hills RK et al (2001) Association between premature mortality and hypopituitarism. West Midlands prospective hypopituitary study group. Lancet 357:425–431

    CAS  PubMed  Google Scholar 

  32. Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd (2016) Testosterone and cardiovascular disease. J Am Coll Cardiol 67:545–557

    CAS  PubMed  Google Scholar 

  33. Santoro N (2011) Update in hyper- and hypogonadotropic amenorrhea. J Clin Endocrinol Metab 96(11):3281–3288

    CAS  PubMed  Google Scholar 

  34. Berinder K, Stackenas I, Akre O, Hirschberg AL, Hulting AL (2005) Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol 63:450–455

    Google Scholar 

  35. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331:904–909

    CAS  PubMed  Google Scholar 

  36. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta- analysis. J Clin Endocrinol Metab 95(43–51):89

    Google Scholar 

  37. Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428–2436

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288

    CAS  PubMed  Google Scholar 

  39. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89:1704–1711

    CAS  PubMed  Google Scholar 

  40. Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and Prolactinomas. Endocrinol Metab Clin N Am 37:67–99

    CAS  Google Scholar 

  41. Casanueva FF, Molitch ME, Schlechte JA et al (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinoma. Clin Endocrinol 65:265–273

    Google Scholar 

  42. Corenblum B, Donovan L (1993) The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59:671–673

    CAS  PubMed  Google Scholar 

  43. Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinemic women. Clin Endocrinol 73:236–242

    CAS  Google Scholar 

  44. Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K et al (2010) High-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroproalctinomas. J Clin Endocrinol Metab 95:2672–2679

    CAS  PubMed  Google Scholar 

  45. Maiter D (2016) Prolactinoma and Pregnancy: From wish to conception. Ann d’ Endocrinol 77:128–134

    Google Scholar 

  46. Boardman HM, Hartley L, Eisinga A, Main C, iFiguls MR, Cosp X, Gabriel Sanchez R, Knight B (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002229.pub4

    Article  PubMed  Google Scholar 

  47. Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, Troendle JF, Nelson LM (2009) Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 94:2277–2283

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Mah PM, Webster J, Jönsson P, Feldt-Rasmussen U, Koltowska-Häggström M, Ross RJ (2005) Estrogen replacement in women of fertile years with hypopituitarism. J Clin Endocrinol Metab 90:5964–5969

    CAS  PubMed  Google Scholar 

  49. Serafini P, Motta EL, White JS (2001) Restoration of ovarian cyclicity and ovulation induction in hypopituitary women. In: Bronstein MD (ed) Pituitary tumors in pregnancy. Kluwer Academic Publishers, Boston, pp 173–194

    Google Scholar 

  50. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ et al (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103:1715–1744

    PubMed  Google Scholar 

  51. Ribeiro RS, Abucham J (2009) Recovery of persistent hypogonadism by clomiphene in male with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 161:163–169

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Vivien Bonert

Authors
  1. Vivien Bonert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vivien Bonert.

Ethics declarations

Conflict of interest

All authors declares that they have no conflict of interest.

Research involving human and animal rights

This article does not contain any studies with human subjects or animals performed by the author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bonert, V. Do nothing but observe microprolactinomas: when and how to replace sex hormones?. Pituitary 23, 307–313 (2020). https://doi.org/10.1007/s11102-020-01039-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-020-01039-x

Keywords

Search

Navigation